Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $11.1 million.

  • Caribou Biosciences' Cash & Equivalents fell 6514.23% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 6514.23%. This contributed to the annual value of $16.3 million for FY2024, which is 6815.41% down from last year.
  • Per Caribou Biosciences' latest filing, its Cash & Equivalents stood at $11.1 million for Q3 2025, which was down 6514.23% from $25.2 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Cash & Equivalents high stood at $435.3 million for Q3 2021, and its period low was $11.1 million during Q3 2025.
  • Over the past 5 years, Caribou Biosciences' median Cash & Equivalents value was $58.3 million (recorded in 2022), while the average stood at $96.1 million.
  • Per our database at Business Quant, Caribou Biosciences' Cash & Equivalents skyrocketed by 167337.35% in 2021 and then plummeted by 8114.33% in 2022.
  • Caribou Biosciences' Cash & Equivalents (Quarter) stood at $240.4 million in 2021, then crashed by 75.73% to $58.3 million in 2022, then fell by 12.3% to $51.2 million in 2023, then plummeted by 68.15% to $16.3 million in 2024, then crashed by 31.6% to $11.1 million in 2025.
  • Its Cash & Equivalents was $11.1 million in Q3 2025, compared to $25.2 million in Q2 2025 and $29.4 million in Q1 2025.